16 / 26
Page 65
conferenceseries
.com
Volume 9
Journal of Biotechnology & Biomaterials
ISSN: 2155-952X
JOINT EVENT
February 28-March 02, 2019 | Berlin, Germany
5
th
International Conference on
Enzymology and Protein Chemistry
&
22
nd
Global Congress on
Biotechnology
Biotechnology 2019
Enzymology 2019
February 28-March 02, 2019
&
Human papillomavirus (HPV): Systemic treatment with Gene-Eden-VIR/Novirin safely and
effectively clears virus
Hanan Polansky, Edan Itzkovitz
and
Adrian Javaherian
The Center for the Biology of Chronic Disease, USA
T
his paper reports the results of a clinical study that tested the effect of systemic treatment with the botanical product Gene-
Eden-VIR/Novirin on the clearance rate (also called time to clearance) of the human papillomavirus (HPV). The study
compared the clearance rate in treated and untreated individuals suffering from a symptomatic HPV infection. The mean
time to clearance in Gene-Eden-VIR/Novirin treated individuals was 5.1 months or 151.5 days (95% CI: 4.2-5.9 months or
95% CI: 125.7-177.3 days respectively). The median time to clearance was 3.5 months. The mean time to clearance in the five
untreated groups ranged from 6.9 to 20.0 months (P<0.0001 for the difference between treatment group and each untreated
group). Also, 100% of the participants in the treatment group were HPV free at the end of 12 months vs., 53%, 52%, 65%, 20%,
and 77% in the untreated control groups. The treated participants reported no adverse experiences. This clinical study has two
major contributions. First, it showed that systemic treatment with the natural Gene-Eden-VIR/Novirin decreased the time of
HPV clearance, increased the percentage of HPV free individuals and caused no adverse experiences in individuals suffering
from a symptomatic HPV infection. Since, there are no other systemic treatments for symptomatic HPV infections, this study
presents highly valuable information on the clinical effects of the first treatment in this category. Secondly, the study presents
a new method for conducting clinical studies that addresses one of the major deficiencies associated with the practice of the
randomized controlled trial method.
hpolansky@cbcd.netJ Biotechnol Biomater 2019, Volume 9
DOI: 10.4172/2155-952X-C2-116